Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1647 CMV vaccine in healthy adults
NCT05085366Phase 3Terminated
- Sponsor
- Moderna Inc
- Start
- Oct 2021
- Primary completion
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 13
01
Overview
A Phase 3 trial of mRNA-1647 in cytomegalovirus infection (CMV), sponsored by Moderna Inc. Started Oct 2021; status: terminated.
02
Drugs
mRNA-1647
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05085366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085366.